We are live on ! Find out more
BLRX

BioLineRX
BLRX

28 hedge funds and large institutions have $13.5M invested in BioLineRX in 2021 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 10 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 2

233% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 3

192% more capital invested

Capital invested by funds: $4.6M → $13.5M (+$8.85M)

33% more funds holding

Funds holding: 21 → 28 (+7)

0.02% more ownership

Funds ownership: 0.01% → 0.03% (+0.02%)

Holders
28
Holders Change
+7
Holders Change %
+33.33%
% of All Funds
0.49%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
10
Reduced
2
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCM
Sio Capital Management
New York
+$8.24M
2
Renaissance Technologies
Renaissance Technologies
New York
+$716K
3
SCM
Silverarc Capital Management
Massachusetts
+$601K
4
SSA
Schonfeld Strategic Advisors
New York
+$123K
5
IP
Intellectus Partners
California
+$122K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$1M
2
Citadel Advisors
Citadel Advisors
Florida
-$124K
3
TNB
Thomasville National Bank
Georgia
-$51K
4
RhumbLine Advisers
RhumbLine Advisers
Massachusetts
-$1.56K
5
SFS
Sowell Financial Services
Arkansas
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
1
Sio Capital Management
New York
$7.65M +$8.24M +68,544 New
Renaissance Technologies
2
Renaissance Technologies
New York
$1.41M +$716K +5,953 +89%
PHP
3
Parkman Healthcare Partners
Connecticut
$1.2M +$6.49K +54 +0.5%
Morgan Stanley
4
Morgan Stanley
New York
$1.11M -$1M -8,345 -46%
SCM
5
Silverarc Capital Management
Massachusetts
$558K +$601K +5,000 New
PVH
6
Psagot Value Holdings
Israel
$326K – – –
SSA
7
Schonfeld Strategic Advisors
New York
$213K +$123K +1,025 +115%
SFI
8
Susquehanna Fundamental Investments
Pennsylvania
$208K +$101K +840 +82%
LPL Financial
9
LPL Financial
California
$184K +$69.7K +580 +54%
IP
10
Intellectus Partners
California
$113K +$122K +1,013 New
CCB
11
Cutter & Co Brokerage
Missouri
$80K – – –
GPFA
12
Game Plan Financial Advisors
Ohio
$74K +$78.2K +650 New
OM
13
Opaleye Management
Massachusetts
$47K – – –
Goldman Sachs
14
Goldman Sachs
New York
$46K +$50K +416 New
Creative Planning
15
Creative Planning
Kansas
$41K +$4.81K +40 +12%
RhumbLine Advisers
16
RhumbLine Advisers
Massachusetts
$38K -$1.56K -13 -4%
RJA
17
Raymond James & Associates
Florida
$35K +$37.9K +315 New
Geode Capital Management
18
Geode Capital Management
Massachusetts
$28K – – –
FHC
19
First Heartland Consultants
Missouri
$28K +$30.1K +250 New
UBS Group
20
UBS Group
Switzerland
$20K +$3.73K +31 +21%
SWM
21
Spire Wealth Management
Virginia
$20K +$21K +175 New
NFG
22
Next Financial Group
Texas
$10K – – –
SPIA
23
Steward Partners Investment Advisory
New York
$3.35K +$240 +2 +7%
CWP
24
Concord Wealth Partners
Virginia
$3K +$3.01K +25 New
Wells Fargo
25
Wells Fargo
California
$2K +$2.04K +17 +1,700%
1
2

BLRX Hedge Fund Activity: Q1 2021 in Review

28 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q1 2021, worth a combined $13.5M — up 192% from $4.6M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new BLRX positions and 3 closed out — a net gain of 7 holders — while 10 added to existing stakes and 2 trimmed.

The largest buyer was Sio Capital Management, opening a new position worth an estimated $8.24M. The largest seller was Morgan Stanley, cutting an estimated $1M.

  • 28 institutional investors held BioLineRX (BLRX) as of Q1 2021, up from 21 in Q4 2020.
  • Funds reported $13.5M of BioLineRX stock for Q1 2021, up 192% quarter-over-quarter.
  • 10 funds opened new BioLineRX positions in Q1 2021 and 3 closed out, a net change of +7 holders.
  • The largest BioLineRX buyer in Q1 2021 was Sio Capital Management, an estimated $8.24M added.
  • The largest BioLineRX seller in Q1 2021 was Morgan Stanley, an estimated $1M sold.

Based on aggregated 13F filings for Q1 2021.